Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

23. April 2026 07:00 ET | Quelle: Kymera Therapeutics, Inc.

Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026

WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
23. April 2026 06:15 ET | Quelle: Equity Insider

The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

Issued on behalf of Avaí Bio, Inc. Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB: AVAI), Eli Lilly and Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Viking Therapeutics,...
23. April 2026 05:45 ET | Quelle: Research and Markets

Central Nervous System (CNS) Biomarkers Global Market Analysis Report 2026: Focus on Alzheimer's, Multiple Sclerosis, ALS, Frontotemporal Dementia, Parkinson's Disease - Forecast to 2030

Dublin, April 23, 2026 (GLOBE NEWSWIRE) -- The "Central Nervous System (CNS) Biomarkers: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.The Central...
23. April 2026 05:16 ET | Quelle: Research and Markets

2025 Protein Synthesis Research Review and Global Market Forecasts to 2030

Dublin, April 23, 2026 (GLOBE NEWSWIRE) -- The "2025 Protein Synthesis Research Review" report has been added to ResearchAndMarkets.com's offering.Key Market Valuations: The global market for...
23. April 2026 04:57 ET | Quelle: Research and Markets

Dermatomycoses Market Report 2025-2035, Profiles of Prominent Players - Kaken Pharma, Novartis, Glenmark Pharma, Sun Pharma, Teva Pharmaceutical, Bayer, and Galderma

Dublin, April 23, 2026 (GLOBE NEWSWIRE) -- The "Dermatomycoses Market - A Global and Regional Analysis: Focus on Drug Type and Region, 2025-2035" report has been added to ResearchAndMarkets.com's...
23. April 2026 04:30 ET | Quelle: Custom Market Insights

Global Automated Insulin Delivery System Market Size/Share Worth USD 2684 Million by 2035 at a 10.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)

Austin, TX, USA, April 23, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Automated Insulin Delivery System Market Size, Trends and Insights By Product...
23. April 2026 04:02 ET | Quelle: Research and Markets

Cancer Biomarkers Market Research Report 2026: Asia Pacific is a High-potential Region Fueled by Increased Healthcare Spending, While Genetic and Epigenetic Segments Drive Innovation

Dublin, April 23, 2026 (GLOBE NEWSWIRE) -- The "Cancer Biomarkers Market - Types, Applications and Technologies" report has been added to ResearchAndMarkets.com's offering.The global market for...
23. April 2026 04:01 ET | Quelle: Research and Markets

Bone Metastasis in Solid Tumors Market Research and Global Long-term Forecast Report 2025-2035 Featuring Mabwell Bioscience, Novartis, Telix Pharmaeuticals, Sichuan Kelun-Biotech

Dublin, April 23, 2026 (GLOBE NEWSWIRE) -- The "Bone Metastasis in Solid Tumors Market - A Global and Regional Analysis: Focus on Country and Region, 2025-2035" report has been added to ...
22. April 2026 17:30 ET | Quelle: Regeneron Pharmaceuticals, Inc.

Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)

Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical trial program CSU is a chronic skin...
22. April 2026 17:30 ET | Quelle: Sanofi Winthrop Industrie

Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria Approval for children aged two to 11 years with...

Vorherige Seite

Nächste Seite